B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
XNCR
XencorFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary-source updates support multiple dated pipeline milestones, and management maintained year-end cash guidance and runway into mid-2028 despite the royalty dispute. If XmAb819 data or autoimmune milestones de-risk the pipeline, the current price could be too discounting for a company with several shots on goal.
Posture
Defensive
Lead driver
Value
What changed
5 setup hits (3d) with net bullish as of 2026-10-28.
What can break
Alexion told Xencor it does not owe additional U.S. Ultomiris royalties and does not intend to make future U.S. payments, creating a live royalty-dispute overhang.
Momentum
96
Value
41
Sentiment
0
Setup hits (3d)
5 · Net Bullish
AI TargetsBase $11.50 · Bull $16.00 · Bear $8.00Analysis 2026-05-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $40.25
Why
Momentum96 · Δ7d -2.5
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 5 setup hits (3d) with net bullish as of 2026-10-28.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Alexion told Xencor it does not owe additional U.S. Ultomiris royalties and does not intend to make future U.S. payments, creating a live royalty-dispute overhang.
- • Core upside is still tied to clinical execution and future readouts across XmAb819, XmAb412, XmAb942, plamotamab, and XmAb657; delays or weak data could pressure the stock.
- • The earnings follow-up still reads as a monitoring story: checked secondary sources indicated the quarter missed expectations, the revenue base is volatile and royalty-linked, and the Alexion/Ultomiris disagreement adds uncertainty on a previously highlighted royalty opportunity.
Catalyst clock
2026-06-30
Post-Q1 digestion of royalty reset and runway
Lead driver: Value · See fundamentals
Momentum
96
8% active weight
Current posture
7d trendImproving
Δ7d
-2.5
Δ21d
+2.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
0
45% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.9
Why this grade
Composite grade F. Momentum 96.3 / Value 40.6 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-16. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$2.23B
Beta
0.99
Shares Out
74.35M
P/E (TTM) · Derived
-24.2
P/S (TTM)
6.09
P/FCF (TTM) · Derived
-10.82
Rev YoY
+17.5%
EPS YoY
-31.0%
Gross Margin
+90.3%
Op Margin
-205.8%
Net Debt
-$359.99M
Current Ratio
6.39
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data